Bank of Ireland was the standout stock on the Dublin market on Monday, according to one analyst. The bank’s shares  finished at 36 cent

European shares reversed early losses and closed up yesterday, with persistent concerns about Greece’s debt situation offset by optimism that a reshu(...)

A generic form of the drug Plavix sits on crates at a Mylan Pharmaceuticals distribution centre. The drug maker Mylan has offered to acquire Perrigo for about $29 billion in what would be the latest mega-merger among drug makers if it is completed. Photograph: Travis Dove/The New York Times

It’s been a busy few weeks for US pharma giant Mylan, which reports quarterly earnings today. Firstly, it made a proposal to buy Dublin-based Perrigo,(...)

Twitter: results out tomorrow.  Photographer: Andrew Harrer/Bloomberg
For Your Diary

TODAY Results: Alkermes; Apple; Bankia; Doosan; Jones Lang LaSalle; Mylan. Meeting: Dragon Oil AGM (Intercontinental Hotel, Park Lane, London) Indi(...)

Robert Coury, chief executive of Mylan pharmacutical company. Photograph: Alan Betson / THE IRISH TIMES

Generic drugmaker Mylan says it will take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profil(...)

Joe Papa CEO and president of Perrigo, which has rejected a $29 billion bid from rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

Teva factory sign on its plant in Jerusalem: Teva says its stock-and-cash offer of $82 a share represented a 48 per cent premium to Mylan’s stock price on March 10th, which it said was the last day of trading prior to the widespread speculation. Photograph: Menahem Kahana

Generic drugmaker Teva Pharmaceutical Industries Ltd yesterday proposed buying Mylan for $40 billion, saying it was a better deal than the smaller riv(...)

An employee collects newly-manufactured pills at the tablet production plant at Teva Pharmaceutical Industries Ltd.’s headquarters in Jerusalem. Photograph: Adam Reynolds/Bloomberg

Generic drugmaker Teva Pharmaceutical Industries said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and c(...)

Joe Papa, CEO and president of Perrigo

The ripple effect of the wave of corporate inversion in the pharma/medtech sector continues to drive the ongoing wave of consolidation.Less than two y(...)

With CRH’s acquisition of Holcim-Lafarge assets dependent on a merger, the Irish company’s shares increased 2.9 per cent to €24.98.

European stocks climbed to a record high amid better-than- estimated German industrial output, and oil rebounded from the biggest decline in two mont(...)

A generic form of the drug Plavix sits on crates at a Mylan Pharmaceuticals distribution centre in North Carolina.  Mylan has offered to acquire Perrigo for about $29 billion in what would be the latest mega-merger among drug makers if it is completed. Photograph: Travis Dove/The New York Times

Drugmaker Mylan offered to buy rival Perrigo for $28.9 billion in a deal that would create a powerhouse for generic medicine. Mylan, which makes abo(...)